C-reactive protein and the biology of disease

Immunologic Research

Volumn 56, Issue 1, 2013, Pages 131-142

  Ansar, Waliza ^a   Ghosh, Shyamasree ^b  

^a ASUTOSH COLLEGE   (India)

^b NATIONAL INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

C reactive protein; Disease; Inflammation

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; PLACEBO; ROSUVASTATIN;

ARTICLE; ATHEROSCLEROSIS; BACTERIAL INFECTION; BURN; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG TARGETING; HEART INFARCTION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INNATE IMMUNITY; LEISHMANIASIS; MALARIA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN STRUCTURE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; TISSUE NECROSIS; VIRUS INFECTION;

ACUTE-PHASE PROTEINS; ANIMALS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, INNATE; IMMUNOMODULATION; INFLAMMATION;

EID: 84876418473     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8384-0     Document Type: Article

References (86)

1. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52:561-71.
2. Macleod CM, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. II. Isolation and properties of the reactive protein. J Exp Med. 1941;73:183-90.
3. Abernethy TJ, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. 1. Distribution of the reactive protein in patient's sera and the effect of calcium on the flocculation reaction with C polysaccharide of Pneumococcus. J Exp Med. 1941;73:173-82.
4. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci. 1982;389:406-18.
5. Li YP, Mold C, Du Clos TW. Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. J Immunol. 1994;152:2995-3005.
6. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38:189-97.
7. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med. 1999;17:1019-25.
8. Du Clos TW. C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J Immunol. 1989;143:2553-9.
9. Du Clos TW, Zlock LT, Rubin RL. Analysis of the binding of C-reactive protein to histones and chromatin. J Immunol. 1988;141:4266-70.
10. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337-66.
11. Pepys MB, Dash AC, Fletcher TC, Richardson N, Munn EA. Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature. 1978;273:168-70.
12. Robey FA, Liu TY. Limulin: a C-reactive protein from Limulus polyphemus. J Biol Chem. 1981;256:969-75.
13. Olafsen JA. Role of lectins (C-reactive protein) in defense of marine bivalves against bacteria. Adv Exp Med Biol. 1995;371A:343-8.
14. Nagpurkar A, Mookerjea S. A novel phosphorylcholine-binding protein from rat serum and its effect on heparin-lipoprotein complex formation in the presence of calcium. J Biol Chem. 1981;256:7440-6.
15. De Beer FC, Pepys MB. Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods. 1982;50:17-31.
16. De Beer FC, Shine B, Pepys MB. Radiometric ligand binding assay for C-reactive protein. Complexed C-reactive protein is not detectable in acute phase serum. Clin Exp Immunol. 1982;50:231-7.
17. Mandal C, Sinha S, Mandal C. Lectin like properties and differential sugar binding characteristics of C-reactive proteins purified from sera of normal and pollutant induced Labeo rohita. Glycoconj J. 1999;16:741-50.
18. Sinha S, Mandal C. Microheterogeneity of C-reactive protein in the sera of fish Labeo rohita induced by metal pollutants. Biochem Biophys Res Commun. 1996;226:681-7.
19. Paul I, Mandal C, Allen AK, Mandal C. Glycosylated molecular variants of C-reactive proteins from the major carp Catla catla in fresh and polluted aquatic environments. Glycoconj J. 2001;18:547-56.
20. Kushner I. The acute phase response: an overview. Methods Enzymol. 1988;163:373-83.
21. McCarty M. The occurrence during acute infections of a protein not normally present in the blood: IV. Crystallization of the C-reactive protein. J Exp Med. 1947;85:491-8.
22. Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med. 1966;123:365-78.
23. Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol. 1996;156:4815-20.
24. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-51.
25. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun. 2001;69:1747-54.
26. Jabs WJ, Logering BA, Gerke P, Kreft B, Wolber EM, Klinger MH, et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol. 2003;33:152-61.
27. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest. 1994;94:1390-6.
28. Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. C-reactive protein binds to FcγRI in transfected COS cells. J Immunol. 1995;155:2185-93.
29. Das T, Sen A, Kempf T, Pramanik SR, Mandal C, Mandal C. Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem J. 2003;373:345-55.
30. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107:370-1.
31. Ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol. 1990;17:1642-8.
32. Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953-66.
33. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564-9.
34. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462-6.
35. Chandrashekara S, Sachin S. Measures in rheumatoid arthritis: are we measuring too many parameters. Int J Rheum Dis. 2012;15:239-48.
36. Galeazzi M, Morozzi G, Veronesi M, Ronconi S, Magi B, Bini L, et al. Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis. Recenti Prog Med. 1995;86:456-62.
37. Wu JF, Yang YH, Wang LC, Lee JH, Shen EY, Chiang BL. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in juvenile rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:782-5.
38. Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum. 1994;24:91-104.
39. Vogt B, Führnrohr B, Müller R, Sheriff A. CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity. 2007;40:295-8.
40. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum. 2008;59:1814-20.
41. Rezaieyazdi Z, Sahebari M, Hatef MR, Abbasi B, Rafatpanah H, Afshari JT, et al. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? Lupus. 2011;20:1494-500.
42. Olson RE. Atherogenesis in children: implications for the prevention of atherosclerosis. Adv Pediatr. 2000;47:55-78.
43. Pereira IA, Borba EF. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly. 2008;138:534-9.
44. Danesh J, Pepys MB. C-reactive protein in healthy and in sick populations. Eur Heart J. 2000;21:1564-5.
45. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-12.
46. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of stain therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-65.
47. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation. 1999;100:230-5.
48. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
49. Emerging Risk Factor Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310-20.
50. Kushner I, Rakita L, Kaplan MH. Studies of acute phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J Clin Invest. 1963;42:286-92.
51. Kushner I, Kaplan MH. Antigenic analysis of extracts of human heart tissue: cardiac antigens with limited distribution in other organs. J Immunol. 1967;99:526-33.
52. Kushner I. C-reactive protein and atherosclerosis. Science. 2002;297:520-1.
53. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733-9.
54. de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta. 2002;317:1-15.
55. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635-41.
56. Tanigaki K, Vongpatanasin W, Barrera JA, Atochin DN, Huang PL, Bonvini E, et al. C-reactive protein causes insulin resistance in mice through Fcγ receptor IIB-mediated inhibition of skeletal muscle glucose delivery. Diabetes. 15 Oct 2012. [in press].
57. Mugabo Y, Li L, Renier G. The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Curr Diabetes Rev. 2010;6:27-34.
58. King DE, Mainous AG 3rd, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003;26:1535-9.
59. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585-90.
60. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250-5.
61. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13:R55.
62. Helzlsouer KJ, Erlinger TP, Platz EA. Creactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer. 2006;42:704-7.
63. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48:155-70.
64. Ansar W, Bandyopadhyay SM, Chowdhury S, Habib SH, Mandal C. Role of C-reactive protein in complement mediated hemolysis in malaria. Glyconj J. 2006;23:233-40.
65. Dongho Dongmo FF, Ngono Ngane RA, Gouado I, Pankoui Mfonkeu JB, Mbackop Kwemba V, et al. Predictors of childhood severe malaria in a densely populated area: Douala, Cameroon. Afr J Biotechnol. 2011;10:6319-24.
66. Nahrevanian H, Gholizadeh J, Farahmand M, Assmar M. Patterns of co-association of C-reactive protein and nitric oxide in malaria in endemic areas of Iran. Mem Inst Oswaldo Cruz. 2008;103:39-44.
67. Bourée P, Botterel F, Lançon A. Comparative study VS-CRP in malaria. Mal. Inf. Dis. Afr. 2000;2-3.
68. Kremsner PG, Winkler S, Wildling E, Prada J, Bienzlz U, Graninger W, Nüssler AK. High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitogical and clinical cure in Plasmodium falciparum malaria. Trans R Trop Med Hyg. 1996;90:44-7.
69. Paul R, Sinha PK, Banerjee AK, Raychaudhuri P, Mondal J. Study of C reactive protein as a prognostic marker in malaria from Eastern India. Adv Biomed Res. 2012;1:1-9.
70. Gjørup IE, Vestergaard LS, Møller K, Rønn AM, Bygbjerg IC. Laboratory indicators of the diagnosis and course of imported malaria. Scand J Infect Dis. 2007;39:707-13.
71. Jakobsen PH, Mckay V, Jie RN, Olaleye BO, D'alessandro U, Zhang GH, et al. Decreased antitoxic activities among children with clinical episodes of malaria. Infect Immun. 1998;66:1654-9.
72. Ansar W, Mandal C, Habib Sk, Roy S, Mandal C. Unraveling the C-reactive protein complement-cascade in destruction of red blood cells: potential pathological implications in Plasmodium falciparum malaria. Cell Physiol Biochem. 2009;23:169-75.
73. Culley FJ, Harris RA, Kaye PM, McAdam KP, Raynes JG. C-reactive protein binds to a novel ligand on Leishmania donovani and increases uptake into human macrophages. J Immunol. 1996;156:4691-6.
74. Culley FJ, Thomson M, Raynes JG. C-reactive protein increases C3 deposition on Leishmania donovani promastigotes in human serum. Biochem Soc Trans. 1997;25:286S.
75. Culley FJ, Bodman-Smith KB, Ferguson MA, Nikolaev AV, Shantilal N, Raynes JG. C-reactive protein binds to phosphorylated carbohydrates. Glycobiology. 2000;10:59-65.
76. Bodman-Smith KB, Mbuchi M, Culley FJ, Bates PA, Raynes JG. C-reactive protein-mediated phagocytosis of Leishmania donovani promastigotes does not alter parasite survival or macrophage responses. Parasite Immunol. 2002;24:447-54.
77. Bee A, Culley FJ, Alkhalife IS, Bodman-Smith KB, Raynes JG, Bates PA. Transformation of Leishmania mexicana metacyclic promastigotes to amastigote-like forms mediated by binding of human C-reactive protein. Parasitology. 2001;122:521-9.
78. Ansari NA, Sharma P, Salotra P. Circulating nitric oxide and C-reactive protein levels in Indian kala azar patients: correlation with clinical outcome. Clin Immunol. 2007;122:343-8.
79. Ansar W, Mukhopadhyay S, Habib SK, Basu S, Saha B, Sen AK, et al. Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis. Glycoconj J. 2009;26:1151-69.
80. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM. 2003;96:793-807.
81. Gasim S, Theander TG, ElHassan AM. High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis. Acta Trop. 2000;75:35-8.
82. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 1982;47:239-43.
83. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J. 2011;162:597-605.
84. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141-212.
85. Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW, et al. Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods. 2012;384:92-102.
86. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7:169-77.